Screener
Altimmune ALT Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Altimmune’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326190-26-000040
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $1,530 | $2,717 |
| Accrued expenses and other current liabilities | 9,793 | 12,280 |
| Total current liabilities | 11,323 | 14,997 |
| Term loan, noncurrent | 34,505 | 34,287 |
| Other noncurrent liabilities | 5,815 | 5,753 |
| Total liabilities | 51,643 | 55,037 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: |
Item 1. Financial Statements
FAQ
- What is Altimmune's long-term debt?
- Altimmune (ALT) reported long-term debt of $34.51M in Q1 2026.
- What is the long-term trend for Altimmune's long-term debt?
- Over 3 years (2020 to 2025), Altimmune's long-term debt has grown at a 165.7% compound annual growth rate (CAGR), from $1.83M to $34.29M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Altimmune's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude